Interim report January – September 2021
Curasight A/S (“Curasight” or the “Company”) hereby publishes the interim report for the period January 1 – September 30, 2021. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.
Curasight’s CEO Ulrich Krasilnikoff comments:
”One year has passed since Curasight was listed on Spotlight Stock Market – a listing that received several awards, which we are very proud of. Every day we continue to advance Curasight’s technology, and I am convinced that we are on the right path towards our mission – to improve the lives of millions of people suffering from cancer. We are currently working on an extension of the strategy in order to unfold further our platform and broaden the mission. We believe this will take Curasight to the next level. We, foresee an interesting news flow in 2022 that will include a number of important value inflection points. We are grateful with the trust and commitment that our shareholders have shown us with the exercise of warrants in October, why the management has decided to extend their lock-up, which currently runs until the end of 2021, meaning that I and CSO Andreas Kjær extend our lock-up with another six months to July 1st 2022.”
2
Q3 (2021-07-01 – 2021-09-30)
- Net sales amounted to 0 (0) DKK
- Operating profit/loss amounted to -807,809 (-218,370) DKK
- Profit/loss before taxes amounted to -1,418,449 (-443,100) DKK
- Profit/loss for the year amounted to -1,106,390 (-345,618) DKK
- Total assets amounted to 59,506,515 (68,720,255) DKK
- Equity ratio amounted to 94.8 (93.0)
- Earnings per share amounted to -0.06 (-0.02)
Q1-Q3 (2021-01-01 – 2021-09-30)
- Net sales amounted to 0 (0) DKK
- Operating profit/loss amounted to -1,579,771 (-365,180) DKK
- Profit/loss before taxes amounted to -3,495,177 (-1,006,465) DKK
- Profit/loss for the year amounted to -2,726,238 (-785,043) DKK
- Total assets amounted to 59,506,515 (68,720,255) DKK
- Equity ratio amounted to 94.8 (93.0)
- Earnings per share amounted to -0.16 (-0.05)
Highlights during the third quarter
- On September 1, Curasight announced that the Company has strengthened its institutional investor base as part of the Company’s future strategy. Arbejdernes Landsbank acquired 200,000 warrants from the Swedish investment company Eastbridge.
- On September 16, the exercise period started for the warrants of series TO 1 that were issued in connection with the issue of units during September 2020.
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.